Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Islatravir→

Islatravir Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
865363-93-5
Molecular formula
C12H12FN5O3
Molecular weight
293.25 g/mol
Drug class
Antiretroviralnucleoside reverse transcriptase translocation inhibitor (NRTTI)
Mechanism of action
A deoxyadenosine nucleoside analogue converted intracellularly to islatravir-triphosphate. The active triphosphate inhibits HIV reverse transcriptase by blocking translocation after incorporation into viral DNA, producing immediate and delayed chain termination.
Indications / reported uses
  • Used as part of the fixed-dose doravirine/islatravir antiretroviral regimen for HIV-1 infection in adults under the applicable product label.

Sources: https://clinicalinfo.hiv.gov/drugs/islatravir/health-professional · https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11aaeb53-9848-433c-be7f-db8a5bc0b26f

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Antiretroviral; nucleoside reverse transcriptase translocation inhibitor (NRTTI)

Mechanism of action

A deoxyadenosine nucleoside analogue converted intracellularly to islatravir-triphosphate. The active triphosphate inhibits HIV reverse transcriptase by blocking translocation after incorporation into viral DNA, producing immediate and delayed chain termination.

General use cases

  • Used as part of the fixed-dose doravirine/islatravir antiretroviral regimen for HIV-1 infection in adults under the applicable product label.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Islatravir Environmental Risk Assessment (ERA) (the Islatravir ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.